What We Know (and Don’t Know) About Bisphosphonates

Many navicular horses have benefited from bisphosphonate treatment, but some questions remain about these medications.

No account yet? Register


What We Know (and Don’t Know) About Bisphosphonates
Many navicular horses have benefited from bisphosphonate treatment, but some questions remain about these medications. | Photo: iStock
In 2014, the U.S Food and Drug Administration (FDA) approved the use of the bisphosphonates tiludronate (Tildren) and clodronate (Osphos) for controlling clinical signs of navicular disease in horses. Since then, however, more questions than answers have surfaced regarding this potentially ground-breaking class of drugs. Katja F. Duesterdieck-Zellmer, DMV, PhD, Dipl. ACVS, assistant professor of large animal surgery at Oregon State University’s Department of Clinical Sciences, in Corvallis, reviewed bisphosphonates and their effects at the 2016 American Association of Equine Practitioners Convention, held Dec. 3-7 in Orlando, Florida.

In humans, physicians use bisphosphonates to prevent loss of bone mass associated with osteoporosis. Among equine practitioners, however, “the use of bisphosphonates seems to be controversial, with many having strong opinions for or against the use of these drugs in equines,” said Duesterdieck- Zellmer. “Questions remain regarding the best choice of bisphosphonate, frequency, route and dose of administration, minimum age of the horse to be treated, what type of conditions may benefit from treatment, and how to select the best candidates from successful bisphosphonate treatment.”

The Pharmacokinetics

Veterinarians can administer bisphosphonates either intravenously (IV) or intramuscularly (IM). Once in the body, the drug binds to bone mineral, particularly at sites of active bone resorption.

“Here, bisphosphonates remain until being liberated via slowed bony resorption,” said Duesterdieck-Zellmer. This means the drug’s half-life (in the case of bisphosphonates, the time it takes for the drugs’ bone concentration to decrease by 50%) depends on the rate of bone turnover, which varies by location and disease state present. There’s currently no data available about bisphosphonates’ half-life in horses

Create a free account with TheHorse.com to view this content.

TheHorse.com is home to thousands of free articles about horse health care. In order to access some of our exclusive free content, you must be signed into TheHorse.com.

Start your free account today!

Already have an account?
and continue reading.


Written by:

Alexandra Beckstett, a native of Houston, Texas, is a lifelong horse owner who has shown successfully on the national hunter/jumper circuit and dabbled in hunter breeding. After graduating from Duke University, she joined Blood-Horse Publications as assistant editor of its book division, Eclipse Press, before joining The Horse. She was the managing editor of The Horse for nearly 14 years and is now editorial director of EquiManagement and My New Horse, sister publications of The Horse.

Related Articles

Stay on top of the most recent Horse Health news with

FREE weekly newsletters from TheHorse.com

Sponsored Content

Weekly Poll

sponsored by:

When do you vaccinate your horse?
393 votes · 393 answers

Readers’ Most Popular

Sign In

Don’t have an account? Register for a FREE account here.

Need to update your account?

You need to be logged in to fill out this form

Create a free account with TheHorse.com!